Business Context and Reporting Period
Company: Zentalis Pharmaceuticals, Inc. (ZNTL)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Zentalis is a clinical-stage biopharmaceutical company focused on developing azenosertib (ZN-c3), an investigational WEE1 inhibitor, primarily for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC). The company has no approved products and generates no product revenue.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $67,425 |
| Net Loss | $(137,060) | $(165,839) |
| Research & Development Expenses | $107,295 | $167,768 |
| General & Administrative Expenses | $37,717 | $87,115 |
| Restructuring Expenses | $7,796 | $0 |
| Cash, Cash Equivalents & Marketable Securities | $245,893 | $371,084 |
| Accumulated Deficit | $(1,191,455) | $(1,054,395) |
| Net Cash Used in Operating Activities | $(125,247) | $(170,860) |
Note: Revenue in 2024 consisted of licensing and asset sale proceeds from Immunome. The company had no debt as of December 31, 2025.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to zero in 2025 from $67.4 million in 2024. The 2024 revenue was driven by the Immunome License Agreement and subsequent asset purchase agreement, which concluded in late 2024.
- Expense Reduction: Total operating expenses decreased by approximately $105.8 million year-over-year.
- R&D: Decreased by $60.5 million, primarily due to reduced clinical expenses, lab services, and personnel costs following a strategic restructuring.
- G&A: Decreased by $49.4 million, largely driven by a $47.1 million reduction in personnel expenses (including $40.8 million in non-cash stock-based compensation).
- Restructuring Costs: The company incurred $7.8 million in restructuring expenses in 2025 related to a workforce reduction of approximately 40% announced in January 2025.
- Stock Repurchase: In December 2025, the company repurchased 7.5 million shares from Matrix Capital Master Fund, LP for approximately $10.0 million ($1.33/share).
Guidance, Outlook, and Risks
Clinical Outlook:
- DENALI Part 2: Enrollment for Part 2a was completed in 2025. Dose selection is expected in the first half of 2026, with a topline readout anticipated by year-end 2026. Success could support accelerated FDA approval.
- ASPENOVA: A Phase 3 confirmatory trial is planned to initiate in the first half of 2026, enrolling concurrently with DENALI Part 2b.
Liquidity and Capital Resources:
- As of December 31, 2025, the company held $245.9 million in cash, cash equivalents, and marketable securities.
- Management believes these resources are sufficient to fund operations into late 2027.
- The company maintains an "at-the-market" (ATM) offering program with $69.5 million remaining available for sale.
Key Risks and Contingencies:
- Dependence on Azenosertib: The company's success is entirely dependent on the development and approval of azenosertib.
- Companion Diagnostic: Regulatory approval of a companion diagnostic to identify Cyclin E1-positive patients is required for commercialization; delays here would impair revenue generation.
- Manufacturing: Reliance on third-party manufacturers, including facilities in China, exposes the company to supply chain disruptions and geopolitical risks (e.g., BIOSECURE Act).
- Regulatory Environment: Potential changes in U.S. healthcare policy, including the Inflation Reduction Act and proposed "Globe and Guard" regulations, could impact future pricing and reimbursement.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $245.9 million cash balance to fund the Phase 3 ASPENOVA trial and potential commercialization without further dilution.
- DENALI Part 2a Results: Monitor the first-half 2026 announcement regarding dose selection from DENALI Part 2a, which is critical for the Phase 3 design.
- Companion Diagnostic Status: Confirm progress on the validation and regulatory approval of the Cyclin E1 companion diagnostic test.
- Manufacturing Supply Chain: Assess the impact of the BIOSECURE Act and potential trade restrictions on the company's reliance on Chinese contract manufacturers.
- Stock-Based Compensation: Review the significant reduction in stock-based compensation ($40.8 million decrease in G&A) and its sustainability as a cost-saving measure.